Clinical Research (Ueno, 2000)
Two clinical trials have shown the benefit of Immudyne's Ultra Pure Beta-1,3/1,6-D-Glucan (YBG).
Clinical Trial #1. Decreased reoccurrence of cancer in cancer remission patients.
| N: | 49 cancer patients in remission (from breast, ovarian and cervical) |
| Dose: | 7.5 mg YBG (2.5 mg tid) |
| Duration: |
15 months |
|
Results:
|
No reoccurrence of cancer in 100% of the 26 study participants ingesting YBG compared to 22% reoccurrence rate found in the matched control group consisting of 23 individuals. |
Clinical Trial #2. Increased survival in terminally-ill cancer patients.
| N: | 99 terminally-ill cancer patients (defined as 3 months or less to live) |
| Dose: |
15 mg YBG (5 mg tid) |
| Duration: |
6 month |
|
Results: |
After three months, only 4% of the 45 in the control group were still alive compared to 65% of the 54 individuals ingesting YBG. After six months, no one in the control group was still living, while 43% of those ingesting YBG were still alive. |
Topical research
Clinical Trial. Effect of topical beta-1,3/1,6-D-glucan on reducing skin wrinkles.
Applied twice daily the Immudyne products reduced the number and intensity of wrinkles in the female study participants significantly. At the initiation of the study the women had an average appearance of 44 years, as determined by their average wrinkle score. By the end of the eight week study the women had an average appearance of 29 years; an improvement of 15 years of skin regeneration in just 8 weeks!
References
Ueno H. Beta-1,3-D-Glucan, its Immune Effect and its Clinical use. Japanese Journal Society Terminal Systemic Diseases 2000;6:151-4.
Other areas of research include
- Animal feed
- Aquaculture
- Cancer treatment
- Wound healing